ZA200903791B - Alphavirus and alphavirus replicon particle formulations and metods - Google Patents

Alphavirus and alphavirus replicon particle formulations and metods

Info

Publication number
ZA200903791B
ZA200903791B ZA200903791A ZA200903791A ZA200903791B ZA 200903791 B ZA200903791 B ZA 200903791B ZA 200903791 A ZA200903791 A ZA 200903791A ZA 200903791 A ZA200903791 A ZA 200903791A ZA 200903791 B ZA200903791 B ZA 200903791B
Authority
ZA
South Africa
Prior art keywords
alphavirus
metods
particle formulations
replicon particle
alphavirus replicon
Prior art date
Application number
ZA200903791A
Other languages
English (en)
Inventor
Roberto A Depaz
Todd L Talarico
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of ZA200903791B publication Critical patent/ZA200903791B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200903791A 2006-11-03 2009-06-01 Alphavirus and alphavirus replicon particle formulations and metods ZA200903791B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86436606P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
ZA200903791B true ZA200903791B (en) 2010-03-31

Family

ID=39110550

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903791A ZA200903791B (en) 2006-11-03 2009-06-01 Alphavirus and alphavirus replicon particle formulations and metods

Country Status (10)

Country Link
US (2) US20090047255A1 (es)
EP (1) EP2099485B1 (es)
AU (1) AU2007317347B2 (es)
CA (1) CA2668417A1 (es)
DK (1) DK2099485T3 (es)
ES (1) ES2673823T3 (es)
IL (1) IL198364A (es)
NZ (1) NZ576563A (es)
WO (1) WO2008058035A1 (es)
ZA (1) ZA200903791B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
WO2010118244A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
HUE026885T2 (en) * 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
JP6023696B2 (ja) 2010-03-31 2016-11-09 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
US9045728B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Liquid viral formulations
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
SG11201507462QA (en) * 2013-03-14 2015-10-29 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
KR101398764B1 (ko) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 입자의 이동에 의해 분석물질을 검출하는 장치 및 방법
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2016165831A1 (en) * 2015-04-17 2016-10-20 Curevac Ag Lyophilization of rna
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
KR20220129567A (ko) 2019-12-31 2022-09-23 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
WO2021221127A1 (en) * 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
EP1860192A1 (en) * 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU2220800A (en) * 1998-12-31 2000-07-31 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
JP4841726B2 (ja) * 1999-02-05 2011-12-21 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスワクチン製剤
PT1242060E (pt) 1999-08-17 2006-08-31 Glaxo Group Ltd Tratamento da doenca metastatica
AR029643A1 (es) * 1999-08-17 2003-07-10 Smithkline Beecham Biolog Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr
CA2410948C (en) * 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
WO2003049764A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
CA2518546C (en) 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ATE420965T1 (de) * 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
MX360727B (es) * 2004-06-01 2018-11-14 Genzyme Corp Composiciones y metodos para evitar la agregacion del vector aav.
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods

Also Published As

Publication number Publication date
US20090047255A1 (en) 2009-02-19
EP2099485A1 (en) 2009-09-16
NZ576563A (en) 2012-09-28
ES2673823T3 (es) 2018-06-25
DK2099485T3 (en) 2018-05-22
CA2668417A1 (en) 2008-05-15
EP2099485B1 (en) 2018-03-21
IL198364A (en) 2017-11-30
IL198364A0 (en) 2011-08-01
US9187729B2 (en) 2015-11-17
WO2008058035A1 (en) 2008-05-15
AU2007317347A1 (en) 2008-05-15
AU2007317347B2 (en) 2014-02-06
US20110182941A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
ZA200903791B (en) Alphavirus and alphavirus replicon particle formulations and metods
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
ZA200810323B (en) Fkbp-l and uses thereof
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
EP2106268A4 (en) DEVICE FOR GENERATING AND DELIVERING AEROSOL
IL194733A0 (en) Photodisinfection delivery devices and methods
ZA201008045B (en) Nanoparticle formulations and uses thereof
IL193522A0 (en) Pseudoinfectious flavivirus and uses thereof
EP2086318A4 (en) NEUROPROTEKTIVE COMPOSITIONS AND METHOD
ZA200902161B (en) Antiobodies and immunoconjugates and uses therefor
LT2064327T (lt) Dbait ir jų panaudojimas
IL194751A0 (en) Drugs and uses
PL2594248T3 (pl) Połączenie składników czynnych i jego zastosowanie
EP2142216A4 (en) PARTICULATE FORMULATIONS AND ITS USES
EP1997777A4 (en) SILICON DIOXIDE POWDER AND ITS USE
HK1133552A1 (en) Carboranylporphyrins and uses thereof
ZA200807614B (en) Buprenorphine derivatives and uses thereof
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP1991233A4 (en) Hydroxypiperidine derivatives and their use
IL195430A0 (en) Arylsulfonamidyl tetralin derivatives and uses thereof
EP1954253A4 (en) NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
ZA200900960B (en) Arylpiperazine derivatives and uses thereof
GB0610059D0 (en) Uses and methods
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof